United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares of the company’s stock, valued at $2,136,900. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Causey also recently made the following trade(s):

• On Friday, January 2nd, Christopher Causey sold 1,000 shares of United Therapeutics stock. The shares were sold at an average price of $500.01, for a total transaction of $500,010.00.

United Therapeutics Trading Up 2.7%

United Therapeutics stock opened at $502.71 on Wednesday. The company has a 50-day moving average price of $481.47 and a 200 day moving average price of $398.76. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The stock has a market cap of $21.65 billion, a P/E ratio of 19.05, a PEG ratio of 4.71 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the business posted $6.39 EPS. As a group, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. UBS Group lifted their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $509.50.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of UTHR. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares in the last quarter. Invesco Ltd. lifted its holdings in United Therapeutics by 90.2% during the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after buying an additional 419,588 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $317,617,000. Assetmark Inc. increased its holdings in shares of United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after acquiring an additional 197,384 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $136,453,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.